复宏汉霖：汉斯状联合化疗一线治疗ES-SCLC日本桥接试验完成首例患者给药

Core Viewpoint - The company has completed the first patient dosing in a bridging trial in Japan for its self-developed drug Hanshu (Sruvelizumab injection) in combination with chemotherapy (carboplatin-etoposide) for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) [1] Group 1 - The trial aims to support the market application of Hanshu in Japan [1] - An international multicenter phase 3 clinical trial comparing Hanshu or placebo in combination with chemotherapy for first-line treatment of ES-SCLC reached its primary endpoint of overall survival (OS) in December 2021 [1]